ArticleJournal of neuro-oncology2019
Survival and prognostic factors in surgically treated brain metastases.
Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases.Frontiers in oncology · 2022Pooled it
- Low-input CSF cfDNA shallow whole-genome sequencing for CNV-based diagnosis and monitoring of leptomeningeal metastasis in lung cancer.Acta neuropathologica communications · 2026Article
- Colorectal cancer metastasis to the brain: A scoping review of incidence, treatment, and outcomes.World journal of gastrointestinal pathophysiology · 2025Article
- A Comprehensive Analysis of the Management of Brain Metastases-Experience from a South-Eastern European Neurosurgical Centre.Medicina (Kaunas, Lithuania) · 2025Article
- The Role of Repeated Surgical Resections for Recurrent Brain Metastases in Older Population.Medicina (Kaunas, Lithuania) · 2024Article
- TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors.Cancer immunology, immunotherapy : CII · 2024Article
- PTEN-restoration abrogates brain colonisation and perivascular niche invasion by melanoma cells.British journal of cancer · 2024Article
- Article
- Analysis of prognostic factors and the role of epilepsy in neurosurgical patients with brain metastases.Surgical neurology international · 2024Article
- Utility of a prognostic assessment tool to predict survival following surgery for brain metastases.Neuro-oncology practice · 2023Article
- Article
- Fluorescein-guided resection of a left frontal pre-rolandic cerebral metastasis: how I do it.Acta neurochirurgica · 2023Article
- Preoperative Prognostic Index for Patients with Brain Metastases-A Population-Based Multi-Centre Study.Cancers · 2023Article
- Prognostic assessment in patients operated for brain metastasis from systemic tumors.Cancer medicine · 2023Article
- Brain metastases in the elderly - Impact of residual tumor volume on overall survival.Frontiers in oncology · 2023Article
- Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.JAMA network open · 2022Article
- Article
- The Clinical Frailty Scale as useful tool in patients with brain metastases.Journal of neuro-oncology · 2022Article
- Breakouts-A Radiological Sign of Poor Prognosis in Patients With Brain Metastases.Frontiers in oncology · 2022Article
- Association between red blood cell distribution width and mortality in patients with metastatic brain tumors: A retrospective single-center cohort study.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
purposeWhile surgery and radiation remain the mainstays of therapy for all patients with brain metastases (BM), the management is moving to a more individualized approach based on the underlying tumor. We sought to identify prognostic factors of both intracranial progression (IC-PFS) and overall survival (OS) in a surgical cohort.
methodsWe retrospectively reviewed the records of 1015 patients treated surgically for BM at Brigham and Women's Hospital (2007-2017). Kaplan-Meier curves were used for OS and IC-PFS and Cox proportional hazards models were built to assess for predictive factors.
resultsCommon origins were lung (43.9%), breast (14.4%), and melanoma (13.8%). Median OS for the cohort was 15.4 months (95% confidence interval [95%CI] 14.1-17.1). Breast cancer (22.1 months, 95%CI 17.8-30.3) and colorectal cancer (10.6 months, 95%CI 7.2-15.4) had the longest and shortest OS, respectively. On multivariable Cox regression, significant prognostic factors of shorter OS were age (HR 1.01, 95%CI 1.01-1.02), number of lesions (HR 1.56, 95%CI 1.28-1.89), extracranial spread at BM diagnosis (HR 1.26, 95%CI 1.05-1.52), and KPS (HR 0.98, 95%CI 0.98-0.99). Regarding molecular factors, all driver mutations in lung adenocarcinoma had a favorable effect (EGFR, HR 0.53, 95%CI 0.31-0.89; ALK, HR 0.28, 95%CI 0.12-0.66; KRAS, HR 0.65, 95%CI 0.47-0.92), triple negative status predicted poor prognosis in breast adenocarcinoma (HR 2.04, 95%CI 1.13-3.69), while no effect of BRAF/NRAS mutations was demonstrated in melanoma BMs.
conclusionsOur results corroborate the role of tumor origin and systemic as well as intracranial spread in OS. Heterogeneity within histologies was further explained by molecular alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.